Craft
Instil Bio

Instil Bio

Product Candidates

2

Mar, 2021

Revenue

$138 K

FY, 2020

Market Capitalization

$626.6 M

2022-09-19

Instil Bio Summary

Company summary

Overview
Instil Bio (formerly Immetacyte, Cellular Therapeutics) is an immuno-oncology company that specializes in cell therapies. Its technology platform is based on the use of tumor-infiltrating lymphocytes (TILs), T-cells isolated from the patient’s tumor that can recognize and destroy cancer. The company leverages TIL technology to treat metastatic melanoma patients.
Type
Public
Founded
2008
HQ
Dallas, TX, US | view all locations
Website
https://instilbio.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Bronson Crouch

    Bronson Crouch, Chief Executive Officer & Chairman

  • Vijay Chiruvolu

    Vijay Chiruvolu, Chief Technical Officer

  • Zachary Roberts

    Zachary Roberts, Chief Medical Officer

  • George Matcham

Operating MetricsView all

Product Candidates

2

Mar, 2021

Office and Laboratory Space, square feet

131.3K

Mar, 2021

LocationsView all

2 locations detected

  • Dallas, TX HQ

    United States

    3963 Maple Ave #350

  • Dallas, TX

    United States

    5949 Sherry Ln #820

Instil Bio Financials

Summary financials

Net income (Q2, 2022)
($59.0M)
Cash (Q2, 2022)
$42.5M
EBIT (Q2, 2022)
($58.7M)
Enterprise value
$592.1M

Footer menu